ISM6210 / Insilico Medicine - LARVOL DELTA

ISM6210, a potent and selective CDK4 inhibitor for the treatment of HR+/HER2- breast cancer (AACR 2026) - "Notably, in human hematopoietic stem cell assays, ISM6210 exhibited an IC50 value about 30-fold higher than the dual CDK4/6 inhibitor Palbociclib against human hematopoietic stem cells, suggesting reduced myelosuppressive potential. In vivo, ISM6210 achieved robust anti-tumor activity at 30 mg/kg BID across multiple HR+ breast cancer xenograft models with notable tumor enrichment.In addition to its robust biological potency and high selectivity, ISM6210 exhibited favorable drug-like properties, including desirable in vitro ADMET profiles, excellent in vivo exposure and clearance, and good oral bioavailability across multiple preclinical species. Collectively, these findings establish ISM6210 as a potent and selective CDK4 inhibitor that delivers strong efficacy and a promising hematologic safety margin for HR+/HER2- breast cancer treatment."

Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CCND1 • HER-2